Innovative Technologies
Commercialized Science
Slider
  • About Qualigen

    Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform.  The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002.  Our therapeutics pipeline includes cancer drug compounds such as AS1411, AS1411-GNP and RAS-F, as well as STARS, a DNA/RNA-based treatment device.  By combining our demonstrated ability to quickly develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville,  we are committed to providing exciting new therapeutic technologies to physicians and patients.

  • Our Technology

    Qualigen’s AS1411 cancer drug uses a specialized segment of DNA, known as an aptamer, to target and destroy tumor cells, without the serious side effects associated with other cancer therapies .  Our AS1411-GNP cancer drug combines this DNA aptamer with gold nanoparticle technology to increase its potency and broaden the potential applications to include combination therapy with radiation and tumor imaging.   The STARS device will use aptamer technology to cleanse a patient’s blood of circulating tumor cells, checkpoints and inflammation factors.  STARS can also be used for infectious disease treatment, where it can capture and remove viruses.  RAS-F is a small-molecule drug designed to inhibit a genetic mutation that can turn a normal cell into a tumor cell.   The company’s flagship product line, FastPack®, combines magnetic particle immunochemistry with innovative disposable packaging technology to provide real-time diagnostic information for cancers and other serious medical conditions.

  • News

    February 4, 2020

    Qualigen Announces New U.S. Patent Issued for its FastPack® Diagnostic Technology

    CARLSBAD, Calif., Feb. 4, 2020 /PRNewswire/ — Qualigen, Inc., a privately-owned company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform, announced today the issuance of U.S. Patent Number D865210, which covers advanced design aspects of Qualigen’s FastPack technology. …

    Read More...
    January 21, 2020

    Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement

    Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, reported that it has entered into…

    Read More...
    April 11, 2019

    Qualigen Enters into Research Agreement for RAS Inhibitor Cancer Drug with University of Louisville (UofL)

    Qualigen, Inc., and the University of Louisville (UofL) today announced that Qualigen has entered into a Sponsored Research Agreement (SRA) with UofL for development of several small-molecule RAS Inhibitor drug candidates.  Under the terms of this Sponsored Research Agreement, Qualigen assumed funding responsibility for this program from April 1, 2019 through September 30, 2020.  RAS…

    Read More...